Thomas Kelly compensation by year
Deciphera Pharmaceuticals Summary Compensation Table · all 3 fiscal years held| Component | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
| Salary | $465,088 | $483,692 | $507,875 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $632,922 | $169,535 | $510,468 |
| Option awards | $2,103,820 | $456,822 | $747,860 |
| Non-equity incentive | $167,432 | $282,960 | $251,398 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $11,600 | $12,200 | $13,200 |
| Total | $3,380,862 | $1,405,209 | $2,030,801 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Deciphera Pharmaceuticals, Inc. DEF 14A filed April 25, 2024, accession 0001654151-24-000012, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Deciphera Pharmaceuticals, Inc. filed document, accession 0001654151-24-000012. Every figure is read from that document and cited to the page and table it appears in. Filed April 25, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 16,488 | $265,951 | — |
| RSU | 13,665 | $220,416 | — |
| RSU | 8,244 | $132,976 | — |
| RSU | 5,550 | $89,522 | — |
| RSU | 1,760 | $28,389 | — |
| Option | 1,758 | — | $54.87 |
| Option | 14,554 | — | $47.79 |
| Option | 42,708 | — | $8.27 |
| Option | 52,171 | — | $15.48 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Deciphera Pharmaceuticals, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Deciphera Pharmaceuticals’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Steven Hoerter | President and Chief Executive Officer | $6,010,712 |
| Dashyant Dhanak | EVP, Chief Scientific Officer | $3,063,207 |
| Matthew Sherman | EVP, Chief Medical Officer | $2,128,911 |
| Thomas Kelly · this page | EVP, Chief Financial Officer & Treasurer | $2,030,801 |
| Daniel Flynn | Founder and Former EVP, Chief Scientific Officer | $1,999,385 |
| Daniel Martin | Chief Commercial Officer | $1,578,908 |
Thomas Kelly's compensation dossier, Deciphera Pharmaceuticals
You have read Thomas Kelly's totals and holdings. The dossier adds each equity grant Deciphera Pharmaceuticals disclosed for Thomas Kelly and Deciphera Pharmaceuticals's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Deciphera Pharmaceuticals compensation record
free company briefThis page is one person within Deciphera Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Deciphera Pharmaceuticals proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Deciphera Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.